東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Interleukin-10 mediated changes in l...

O'Connor, Colleen Marie.

FindBook

Google Book

Amazon

博客來

Interleukin-10 mediated changes in lung carcinoma cells: Possible effect on tumor growth in vitro.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Interleukin-10 mediated changes in lung carcinoma cells: Possible effect on tumor growth in vitro./
作者:	O'Connor, Colleen Marie.
面頁冊數:	191 p.
附註:	Adviser: Donald A. Cohen.
Contained By:	Dissertation Abstracts International69-02B.
標題:	Health Sciences, Immunology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3301322
ISBN:	9780549462224

Interleukin-10 mediated changes in lung carcinoma cells: Possible effect on tumor growth in vitro.
O'Connor, Colleen Marie.

Interleukin-10 mediated changes in lung carcinoma cells: Possible effect on tumor growth in vitro. - 191 p.

Adviser: Donald A. Cohen.

Thesis (Ph.D.)--University of Kentucky, 2008.

Keywords: Intedeukin-10, JSI-124, Lung Cancer, STAT3, Apoptosis.

ISBN: 9780549462224Subjects--Topical Terms:

1017716
Health Sciences, Immunology.

Interleukin-10 mediated changes in lung carcinoma cells: Possible effect on tumor growth in vitro.
LDR:03360nam 2200301 a 45 001 947104
005 20110523
008 110523s2008 ||||||||||||||||| ||eng d
020 $a 9780549462224
035 $a (UMI)AAI3301322
035 $a AAI3301322
040 $a UMI $c UMI
100 1 $a O'Connor, Colleen Marie. $3 1270523
245 1 0 $a Interleukin-10 mediated changes in lung carcinoma cells: Possible effect on tumor growth in vitro.
300 $a 191 p.
500 $a Adviser: Donald A. Cohen.
500 $a Source: Dissertation Abstracts International, Volume: 69-02, Section: B, page: 0921.
502 $a Thesis (Ph.D.)--University of Kentucky, 2008.
520 $a Keywords: Intedeukin-10, JSI-124, Lung Cancer, STAT3, Apoptosis.
520 $a Poor prognosis in Non Small Cell Lung Carcinoma (NSCLC) patients correlates with elevated Interleukin-10 (IL-10) serum levels. Elevated IL-10 serum levels can indicate an increased rate of recurrent tumors and metastases, decreased responsiveness to chemotherapy and radiation, and decreased survival time. IL-10 can act directly as an autocrine factor that could alter immunogenicity, expression of angiogenic factors and matrix metalloproteases, proliferation, or cell survival. These studies focused on the direct effects of IL-10 on lung tumor cells using murine adenocarcinoma cell lines: Lewis Lung (LL2) Line 1 Neo, MLE-12 MLE-15, and squamous cell line: KLN 205. Studies demonstrated the presence of both IL-10 receptor chains on all cell lines, with none of the cell lines producing IL-10 endogenously. The IL-10 signaling pathway was considered functional by the up-regulation of Suppressor of Cytokine Signaling 3 (SOCS3) message expression in response to exogenous IL-10. IL-10 modified the MHC I and II message in all five cell lines, but did not modify protein expression. Vascular Endothelial Growth Factor (VEGF), Angiopoieten 1, and Angiopoieten 2 message expression were altered by IL-10 in a cell line and cell density dependent manner. IL-10 did not affect proliferation or cell cycle. However, IL-10 enhanced the general viability of the tumor cells and promoted resistance to apoptosis in all cell lines. IL-10 pretreatment of LL2 cells resulted in the delayed movement into early and late apoptosis when cells were subjected to ionizing irradiation, UV-C irradiation, or cisplatin. Cytotoxic T cell mediated lysis of LL2 cells was decreased significantly following IL-10 pretreatment of the tumor cells. IL-10 increased Akt phosphorylation, NFkappaB activation, STAT3 tyrosine phosphorylation; and decreased Jnk phosphorylation and caspase 3 cleavage in LL2 cells. The Janus kinase (JAK1) inhibitor, JSI-124, induced apoptosis in cells, but was abrogated by IL-10 pretreatment. This observation suggests that IL-10 mediates apoptosis resistance through a pathway that is independent of STAT3 tyrosine phosphorylation. These results suggest that a primary effect of IL-10 on lung tumor cells may be increased cell survival in the face of chemo/radiotherapy or cytotoxic T cell attack, resulting in poorer prognosis for NSCLC patients.
590 $a School code: 0102.
650 4 $a Health Sciences, Immunology. $3 1017716
650 4 $a Health Sciences, Oncology. $3 1018566
650 4 $a Health Sciences, Toxicology. $3 1017752
690 $a 0383
690 $a 0982
690 $a 0992
710 2 $a University of Kentucky. $3 1017485
773 0 $t Dissertation Abstracts International $g 69-02B.
790 $a 0102
790 1 0 $a Cohen, Donald A., $e advisor
791 $a Ph.D.
792 $a 2008
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3301322